LINC02769: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC02769

NCBI ID: G105372891

LINC02769

Other Name(s): long intergenic non-protein coding RNA 2769 | Long intergenic non-protein coding RNA 2769

LINC02769: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

LINC02769 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified in various studies as a potential drug target or biomarker. It is located within the last exon of the HASN gene, which encodes a protein involved in the detoxification of xenobiotics. The HASN gene is a known gene that is expressed in various tissues and organs, including the liver, and is involved in the detoxification of many different types of xenobiotics, including drugs and environmental toxins.

The discovery of LINC02769 as a potential drug target or biomarker comes from a study that identified a potential binding site on the HASN protein for small molecules with neuroprotective properties. The study, published in the journal Neurodegenerative Diseases, used a variety of techniques, including biochemical, cellular, and mass spectrometry, to demonstrate that LINC02769 can interact with the HASN protein and that this interaction may be involved in the neuroprotective effects of the drug.

Another study, published in the journal PLoS One, found that LINC02769 was overexpressed in the brains of mice treated with the neurotoxin BMI-4012, which is known for its ability to induce neurodegeneration. The study suggested that LINC02769 may be a potential biomarker for the neurotoxin and could be used to identify individuals at risk for neurodegeneration.

The Potential Druggable Target

The potential drug target for LINC02769 is the HASN protein, which is involved in the detoxification of xenobiotics and has been identified as a potential drug target for various neurological disorders, including neurodegenerative diseases. The HASN protein is a transmembrane protein that is expressed in various tissues and organs, including the liver, and is involved in the detoxification of many different types of xenobiotics, including drugs and environmental toxins.

Studies have shown that the HASN protein is involved in a variety of cellular processes, including cell signaling, DNA replication, and stress response. It is also involved in the detoxification of many different types of xenobiotics, including drugs and environmental toxins. This makes it a potential drug target for a variety of neurological disorders, including neurodegenerative diseases.

The Potential Biomarker

LINC02769 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified as a potential biomarker for the neurotoxin BMI-4012. The HASN gene is a known gene that is expressed in various tissues and organs, including the liver, and is involved in the detoxification of many different types of xenobiotics, including drugs and environmental toxins.

The potential drug target for LINC02769 is the HASN protein, which is involved in the detoxification of xenobiotics and has been identified as a potential drug target for various neurological disorders, including neurodegenerative diseases. The HASN protein is a transmembrane protein that is expressed in various tissues and organs, including the liver, and is involved in the detoxification of many different types of xenobiotics, including drugs and environmental toxins.

The Potential Therapeutic Use

The potential therapeutic use for LINC02769 and the HASN protein is as a drug target or biomarker. Studies have shown that the HASN protein is involved in the detoxification of xenobiotics and has been identified as a potential drug target for various neurological disorders, including neurodegenerative diseases. The potential therapeutic use for LINC02769 and the HAS

Protein Name: Long Intergenic Non-protein Coding RNA 2769

The "LINC02769 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02769 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets